Inhaler Emissions and the Path to Climate Conscious Medicine | MGR | 6 May 2026

Why It Matters

Inhaler emissions represent a sizable, avoidable share of health‑care’s carbon footprint; reducing them can lower both climate impact and health‑care costs, accelerating progress toward net‑zero goals.

Key Takeaways

• Healthcare emits 6.5% of US greenhouse gases, surpassing aviation.
• Metered‑dose inhalers generate 70% of inhaler emissions, 1.15 Mt CO2e.
• Switching to dry‑powder inhalers cuts carbon footprint dramatically.
• Policy gaps hinder inhaler reform; cost and clinical constraints persist.
• Sustainable prescribing and specialist referrals can reduce emissions and costs.

Summary

The presentation highlighted the growing climate crisis and its direct implications for the U.S. health‑care sector, noting that 2024 was the warmest year on record and that emissions must peak before 2025 to stay within the Paris Agreement’s 1.5 °C target. Health‑care contributes 6.5% of domestic greenhouse‑gas emissions—more than aviation—and the sector’s per‑capita footprint is the highest among OECD nations.

A deep dive into inhaler‑related emissions revealed that metered‑dose inhalers (MDIs) dominate the picture, accounting for roughly 70% of inhaler‑related CO₂e and 38% of associated costs. In 2022, Medicare and Medicaid claims for MDIs produced about 1.15 million metric tons of CO₂e, equivalent to the annual electricity use of over 226,000 homes. By contrast, dry‑powder and soft‑mist inhalers emit less than one kilogram of CO₂e each, underscoring a stark disparity in carbon intensity across device types.

The speaker cited recent life‑cycle analyses and longitudinal studies showing a 24% rise in inhaler emissions over a decade, with generic albuterol MDIs responsible for two‑thirds of the impact. Barriers to switching include higher costs for dry‑powder devices, formulary preferences, and clinical suitability—especially for young children. Nonetheless, evidence from Europe suggests that guideline‑concordant prescribing, reduced over‑reliance on short‑acting bronchodilators, and specialist‑driven biologic therapies can curb both emissions and health‑care spending.

Implications are clear: without coordinated policy action—such as enforcing the Kigali Amendment’s HFC phase‑down and incentivizing low‑carbon inhaler options—health‑care’s climate footprint will continue to grow. Stakeholders must align sustainability goals with clinical outcomes, leveraging prescribing reforms and emerging propellant technologies to achieve meaningful decarbonization.

Original Description

This Stanford Department of Medicine Grand Rounds (MGR) presentation is entitled "Inhaler Emissions and the Path to Climate Conscious Medicine," and took place May 6, 2026 on Stanford campus.

Presenter Jyothi Tirumalasetty, MD, is a trailblazing allergist and immunologist at Stanford known for her advances in biologics for asthma, her research on health inequity in food allergy, and her pioneering Green Inhaler Pilot Project promoting sustainable prescribing across Stanford Health Care.

Learn more about the MGR series at: https://medicine.stanford.edu/education/medicine-grand-rounds.html